Abstract 2713: Adenovirus E1A binding to p300 is essential for synergistic cell killing in combination with chemotherapeutic drugs in prostate cancer cells

2012 ◽  
Author(s):  
Hector R. Maya-Pineda ◽  
Enrique Miranda-Rota ◽  
Nick R. Lemoine ◽  
Gunnel Halldén
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Cell Killing ◽  
Chemotherapeutic Drugs ◽  
Prostate Cancer Cells ◽  
Adenovirus E1a

scholarly journals Sensitivity of human prostate cancer cells to chemotherapeutic drugs depends on EndoG expression regulated by promoter methylation

2008 ◽  
Vol 270 (1) ◽  
pp. 132-143 ◽  
Author(s):  
Xiaoying Wang ◽  
Volodymyr Tryndyak ◽  
Eugene O. Apostolov ◽  
Xiaoyan Yin ◽  
Sudhir V. Shah ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Promoter Methylation ◽  
Human Prostate ◽  
Chemotherapeutic Drugs ◽  
Human Prostate Cancer ◽  
Prostate Cancer Cells

KLK5 gene expression is severely upregulated in androgen-independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone

2010 ◽  
Vol 391 (4) ◽  
Author(s):  
Konstantinos Mavridis ◽  
Maroulio Talieri ◽  
Andreas Scorilas
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Chemotherapeutic Agents ◽  
Chemotherapeutic Drugs ◽  
Quantitative Real Time Pcr ◽  
Prostate Cancer Cells ◽  
Diagnosis And Prognosis ◽  
Mtt Method ◽  
Du145 Cells ◽  
Hormone Refractory

AbstractKallikrein-related peptidases (KLKs), includingKLK5, have been proposed as promising biomarkers for prostate cancer diagnosis and prognosis. In the present study, we report that distinct augmentations (up to 6.4-fold) ofKLK5mRNA expressional levels, calculated via quantitative real-time PCR, occur after treatment of DU145 cells with appropriate concentrations, determined by the MTT method, of docetaxel and mitoxantrone. Our data reveal the endogenous need of prostate cancer cells for modifiedKLK5expression to cope with the administration of chemotherapeutic drugs. Furthermore, it is proposed that the expression profile ofKLK5could serve as a putative biomarker for monitoring the treatment response in hormone refractory prostate cancer patients.

Sign in / Sign up

Export Citation Format

Share Document